Literature DB >> 18279455

Targeting CD56 by the maytansinoid immunoconjugate IMGN901 (huN901-DM1): a potential therapeutic modality implication against natural killer/T cell malignancy.

Kenji Ishitsuka, Shiro Jimi, Victor S Goldmacher, Olga Ab, Kazuo Tamura.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18279455     DOI： 10.1111/j.1365-2141.2008.07000.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  10 in total

1.  The clinical characteristics of CD7+ CD56+ acute myeloid leukemias other than M0.

Authors:  Ritsuro Suzuki; Shigeki Ohtake; Jin Takeuchi; Masami Nagai; Yoshihisa Kodera; Motohiro Hamaguchi; Shuichi Miyawaki; Takahiro Karasuno; Shigetaka Shimodaira; Ryuzo Ohno; Shigeo Nakamura; Tomoki Naoe
Journal:  Int J Hematol       Date:  2010-01-29       Impact factor: 2.490

2.  Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program.

Authors:  Andrew C Wood; John M Maris; Richard Gorlick; E Anders Kolb; Stephen T Keir; C Patrick Reynolds; Min H Kang; Jianrong Wu; Raushan T Kurmasheva; Kathleen Whiteman; Peter J Houghton; Malcolm A Smith
Journal:  Pediatr Blood Cancer       Date:  2013-06-24       Impact factor: 3.167

Review 3.  Extranodal natural killer/T-cell lymphoma: current concepts in biology and treatment.

Authors:  Holbrook Kohrt; Ranjana Advani
Journal:  Leuk Lymphoma       Date:  2009-11

4.  Semi-mechanistic population pharmacokinetic model of multivalent trastuzumab emtansine in patients with metastatic breast cancer.

Authors:  V L Chudasama; F Schaedeli Stark; J M Harrold; J Tibbitts; S R Girish; M Gupta; N Frey; D E Mager
Journal:  Clin Pharmacol Ther       Date:  2012-09-12       Impact factor: 6.875

5.  Maytansinoid immunoconjugate IMGN901 is cytotoxic in a three-dimensional culture model of multiple myeloma.

Authors:  Brittany A Nierste; Ellen J Gunn; Kathleen R Whiteman; Robert J Lutz; Julia Kirshner
Journal:  Am J Blood Res       Date:  2016-05-18

6.  ADVL1522: A phase 2 study of lorvotuzumab mertansine (IMGN901) in children with relapsed or refractory wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor, or synovial sarcoma-A Children's Oncology Group study.

Authors:  James I Geller; Joseph G Pressey; Malcolm A Smith; Rachel A Kudgus; Mariana Cajaiba; Joel M Reid; David Hall; Donald A Barkauskas; Stephen D Voss; Steve Y Cho; Stacey L Berg; Jeffrey S Dome; Elizabeth Fox; Brenda J Weigel
Journal:  Cancer       Date:  2020-09-11       Impact factor: 6.860

7.  Absence of polysialylated NCAM is an unfavorable prognostic phenotype for advanced stage neuroblastoma.

Authors:  Miikka Korja; Anne Jokilammi; Toivo T Salmi; Hannu Kalimo; Tarja-Terttu Pelliniemi; Jorma Isola; Immo Rantala; Hannu Haapasalo; Jukka Finne
Journal:  BMC Cancer       Date:  2009-02-17       Impact factor: 4.430

8.  EpCAM aptamer-functionalized polydopamine-coated mesoporous silica nanoparticles loaded with DM1 for targeted therapy in colorectal cancer.

Authors:  Yang Li; Yanhong Duo; Shiyun Bao; Lisheng He; Kai Ling; Jinfeng Luo; Yue Zhang; Hao Huang; Han Zhang; Xiaofang Yu
Journal:  Int J Nanomedicine       Date:  2017-08-26

Review 9.  Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets.

Authors:  Carlos Cuesta-Mateos; Ana Alcaraz-Serna; Beatriz Somovilla-Crespo; Cecilia Muñoz-Calleja
Journal:  Front Immunol       Date:  2018-01-17       Impact factor: 7.561

10.  CD56-Negative Aggressive NK Cell Leukemia Relapsing as Multiple Cranial Nerve Palsies: Case Report and Literature Review.

Authors:  M Guerreiro; F Príncipe; M J Teles; S Fonseca; A H Santos; E Fonseca; P Gomes; C Marques; M Lima
Journal:  Case Rep Hematol       Date:  2017-10-15
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.